Title:

High Seroconversion Rates Amongst Black and Hispanics With Hematologic Malignancies after SARS-CoV-2 Vaccination

Lauren C Shapiro,¹ Astha Thakkar,¹ Radhika Gali,¹ Jesus D Gonzalez-Lugo,¹ Abdul-Hamid Bazarbachi,² Shafia Rahman,¹ Kith Pradhan,¹ Karen Fehn,¹ Michelly Abreu,¹ Noah Kornblum,¹ Kira Gritsman,¹ Mendel Goldfinger,¹ Aditi Shastri,¹ Ioannis Mantzaris,¹ Ira Braunschweig,¹ Balazs Halmos,¹ Amit Verma,¹ Margaret McCort,² Lizamarie Bachier-Rodriguez,¹ and R. Alejandro Sica¹

¹Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; ²Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; ³Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.

Corresponding Author:

R. Alejandro Sica, MD
Department of Oncology
Montefiore Medical Center
Albert Einstein College of Medicine
111 East 210th Street
Bronx, NY 10467
P: 718-920-4826
F: 718-798-7474
Email: asica@montefiore.org

Abstract:

It is well established that COVID-19 carries a higher risk of morbidity and mortality in patients with hematologic malignancies, however, very little data on ethnicity specific responses in this particular patient population currently exist. We established a program of rapid vaccination and evaluation of antibody-mediated response to all EUA COVID-19 vaccines in an inner city minority population to determine the factors that contribute to the poor seroconversion to COVID-19 vaccination in this population. We conducted a cross-sectional cohort study of 126 patients with hematologic malignancies in the outpatient practices of our institution who completed their vaccination series with one of the three FDA EUA COVID-19 vaccines, Moderna, Pfizer, or Johnson & Johnson (J&J). We qualitatively measured Spike IgG production in all patients using the AdviseDx SARS-CoV-2 IgG II assay and quantitatively in 106 patients who completed their vaccination series with at least 14 days after the 2nd dose of the Moderna or Pfizer vaccines or 28d after the single J&J vaccine. Patient characteristics were analyzed using standard descriptive statistics and associations between patient characteristics, cancer subtypes, treatments, and vaccine response were assessed using Fisher Exact test or Kruskal-Wallis Rank Sum test. The majority of patients (74%) were minorities. Seventy patients (60%) received Pfizer, 36 patients (31%) Moderna, and 10 patients (9%) J&J. We observed a high-rate of seropositivity (86%) with 16 pts (14%) having a negative Spike IgG. Of the 86 minority patients included, 94% Blacks (30/32) and 87% (39/45)

Hispanics showed seropositivity. The factors that contributed to significantly lower seroconversion rates included patients with Non-Hodgkin lymphoma ($p=0.005$), those who received cytotoxic chemotherapy ($p=0.002$), IVIG ($p=0.01$), CAR-T cell therapy ($p=0.00002$), and CD20 monoclonal antibodies (Ab) ($p=0.0000008$). Plasma cell neoplasms ($p=0.02$), immunomodulatory agents ($p=0.01$), and proteasome inhibitors ($p=0.01$) had significantly higher seroconversion rates, and those with a history of prior COVID-19 (11%, 12/106) had significantly higher antibody titers ($p=0.0003$). The positivity rate was 86% (37 seropositive, 6 seronegative) for autologous HSCT and 75% (3 seropositive, 1 seronegative) for allogeneic HSCT. No life-threatening AE were observed. We show high seroconversion rates after SARS-CoV-2 vaccination in non-White patients with hematologic malignancies treated with a wide spectrum of therapeutic modalities. Vaccination is safe, effective, and should be encouraged in most patients with hematologic malignancies. Our minorities based study could be employed as an educational tool to dispel myths and provide data driven evidence to overcome vaccine hesitancy.

It is well established that COVID-19 carries a higher risk of morbidity and mortality in patients with hematologic malignancies.^{1,2} The mRNA-based vaccines BNT162b2 (Pfizer) and mRNA-1273 (Moderna), and adenovirus-based Ad26.COV2.S (Johnson & Johnson) vaccine have robust safety and efficacy against COVID-19 among immunocompetent individuals, however, patients with cancer were not enrolled in these registration trials.³⁻⁵ Emerging evidence suggests that despite the three COVID-19 vaccines with emergency use authorization (EUA) by the FDA inducing high levels of immunity in the general population, patients with hematologic malignancies have lower rates of seroconversion for the SARS-CoV-2 Spike IgG antibody (Spike IgG) and thus possibly lower protection against severe COVID-19.⁶⁻⁸ In particular, smaller subgroups of patients with certain hematologic malignancies including chronic lymphocytic leukemia (CLL), multiple myeloma, and patients treated with B-cell depleting therapies (i.e. anti-CD20 monoclonal antibodies (MoAb), chimeric antigen receptor T-cell [CAR-T] therapy) and hematopoietic stem cell transplantation (HSCT), have shown markedly impaired antibody-mediated responses to COVID-19 vaccines.⁹⁻¹² There currently exists, however, very little data on ethnicity specific responses in this particular patient population. We established a program of rapid vaccination and evaluation of antibody-mediated response to all EUA COVID-19 vaccines in an inner city minority population to determine the factors that contribute to the poor seroconversion to COVID-19 vaccination in a broad range of patients with hematologic malignancies.

We conducted a cross-sectional cohort study of patients with hematologic malignancies in the outpatient practices of our institution between March 29, 2021 and July 8, 2021.

Participants were enrolled after signing informed consent if they received one of the three FDA EUA COVID-19 vaccines, Moderna, Pfizer, or Johnson & Johnson (J&J). We qualitatively and quantitatively measured Spike IgG production using the AdviseDx SARS-CoV-2 IgG II assay designed to detect IgG antibodies directed against the receptor-binding domain of the S1 subunit of the SARS-CoV-2 spike protein. This assay has shown high sensitivity (95.6%) and 100% positive percent agreement with other platforms in both the post-COVID-19 infection and post-vaccination settings.¹³

Quantitative analysis was performed on patients who completed their vaccination series at least 14 days after the second dose of the mRNA-based vaccines, or 28 days after the single J&J vaccine. Patient characteristics were analyzed using standard descriptive statistics and associations between patient characteristics, cancer subtypes, treatments, and vaccine response were assessed using Fisher Exact test (categorical variables) or Kruskal-Wallis Rank Sum test (categorical and ordinal variables). Statistical significance was determined at $\alpha < 0.05$. All analyses were performed in R (version 3.6.2). Study protocol, data collection, and analysis was approved by Montefiore Medical Center Institutional Review Board.

A total of 121 patients were enrolled by informed consent and another 10 patients included by retrospective chart review. Five patients did not have Spike IgG performed after consent and excluded. Ten patients had Spike IgG testing before vaccination series completion and excluded from quantitative analysis. A total of 116 patients were included in immunogenicity analysis and 106 patients in quantitative analysis. Baseline characteristics and representative hematologic malignancies are listed in Table 1. The

majority of patients (74%) were minorities. Seventy patients (60%) received Pfizer, 36 patients (31%) Moderna, and 10 patients (9%) J&J. Median time from vaccination completion to Spike IgG was 40 days. We observed a high-rate of seropositivity, 86% (100 patients) with 14% (6 patients) having a negative Spike IgG. Of the 86 minority patients included, 94% Blacks (30/32) and 87% (39/45) Hispanics showed seropositivity. Median Spike IgG titer was 2157 AU/mL (1697 AU/mL, 5290 AU/mL, and 1078 AU/mL for Pfizer, Moderna, and J&J respectively), although percent positivity and titer was not statistically significant between vaccine types. We observed significantly lower seroconversion rates (70%) in patients with lymphoid malignancies, specifically Non-Hodgkin lymphoma ($p=0.005$); however, the seropositive rate was 96% and 98% in patients with myeloid and plasma cell neoplasms respectively. Patients who received cytotoxic chemotherapy ($p=0.002$), IVIG ($p=0.01$), CAR-T therapy ($p=0.00002$), and anti-CD20 MoAb ($p=0.0000007$), especially within 6 months of Spike IgG evaluation ($p=0.02$), also showed significantly lower seroconversion rates. Use of BCL2 inhibitors ($p=0.04$), anti-CD20 MoAb ($p=0.0009$), CAR-T therapy ($p=0.01$), BTK inhibitors ($p=0.04$), current steroid use ($p=0.002$), and IVIG ($p=0.003$) also correlated with significantly lower antibody titers with a trend toward lower antibody titers in patients on any active cancer therapy at time of vaccination ($p=0.051$). Plasma cell neoplasms ($p=0.02$), immunomodulatory agents ($p=0.01$), and proteasome inhibitors ($p=0.01$) had significantly higher seroconversion rates, and patients with history prior COVID-19 (11%, 12/106) had significantly higher antibody titers ($p=0.0003$). Of 47 patients who received HSCT, 43 received an autologous HSCT and 4 an allogeneic HSCT. Median time to HSCT was 30.1 months. The positivity rate was 86% (37 seropositive, 6

seronegative) for autologous HSCT and 75% (3 seropositive, 1 seronegative) for allogeneic HSCT with no significant association with seroconversion, antibody titer, or time (greater or less than 1 year) since transplant. All patients who received anti-CD19 (Axi-cel) CAR-T therapy (0/6) were seronegative, and 1 patient that received BCMA-directed CAR-T therapy (Cilta-cel) was seropositive with no association between timing CAR-T cell infusion (greater or less than 1 year) and seroconversion or titer (median time to CAR-T therapy 17.5 months). The majority of patients, 64% and 53%, reported no adverse effects (AE) to the 1st and 2nd dose respectively. The most common AE were mild in severity and included sore arm, muscle aches, fatigue, and fever. No life-threatening AE were observed.

Collectively, our data mirrors the current literature showing significantly lower rates of seroconversion in recipients following highly immunosuppressive therapies such as anti-CD20 therapies, and CAR-T therapy; however, we also noted that patients simply on cytotoxic chemotherapy are also at risk of poor seroconversion. Similar to the recent prospective cohort registry study through the Leukemia and Lymphoma Society,¹⁴ we have noted that patients with myeloid malignancies and plasma cell neoplasms do quite well with COVID-19 vaccination despite their treatment history, with immunomodulatory agents and proteasome inhibitors actually correlating with higher seroconversion rates. We also observed an 86% seroconversion rate in autologous transplant recipients, higher than the previously reported 66%.¹² Recent anti-CD20 therapy (less than 6 months) and any time post CD19 CAR-T therapy predicts high rates of seronegativity showing that these therapies suppress normal B cell function for long

durations after dosing.^{15,16} It may be important to vaccinate all CAR-T therapy patients prior to lymphodepleting chemotherapy and consider treatment interruption for those patients on anti-CD20 therapy when feasible. In addition, despite our concordant findings with the current literature, race has not been a topic of discussion for successful seroconversion after vaccination. It is well known that race is an important contributor to morbidity and mortality in patients with COVID-19,¹⁷ especially in the hematologic malignancy population, with non-White patients having a significantly higher risk of mortality than White patients,¹ and a higher rate of vaccine hesitancy.¹⁸ Most studies described thus far do not stratify by race with those that do only ranging between 3.5-20% non-White patients.

To our knowledge, this is the first report on high seroconversion rates after SARS-CoV-2 vaccination in non-White patients with hematologic malignancies treated with a wide spectrum of therapeutic modalities. Vaccination is safe, effective, and should be encouraged in patients with hematologic malignancies. Our minorities based study could be employed as an educational tool to dispel myths and provide data driven evidence to overcome vaccine hesitancy.

Acknowledgments

We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund.

Authorship Contributions

LCS, AT, BH, AV, LB-R, and AS designed the study. LCS, RG, AT, JDG-L, AHB, SR, KF, MA, NK, KG, MG, AS, IM, IB, BH, AV, MC, LBR and AS participated in patient recruitment and data collection. KP and LCS analyzed and interpreted the data. LCS wrote the first draft of manuscript and AT and AS provided a critical review of the letter's content. All authors reviewed the manuscript and approved the final letter.

Correspondence: Dr. R. Alejandro Sica, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY, 10467; email: asica@montefiore.org.

Disclosure of Conflicts of Interest

KG has received research funding from iOnctura. AS has received research funding from Kymera Therapeutics, Honoraria from Onclive, Consulting fees from Guidepoint & GLG. AV has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Stelexis Therapeutics. AS serves as a consultant with Morphosys and Miragen and is on the faculty at Physicians' Education Research. The remaining authors declare no competing financial interests.

References

1. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. *Blood*. 2020;136(25):2881-2892.
2. Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. *Blood Advances*. 2020;4(23):5966-5975.
3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;382(27):2603-2615.
4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Eng J Med*. 2020;384(5):403-416.
5. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Eng J Med*. 2020;384(23):2187-2201.
6. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer Cell*. 2021;39:1-10.
7. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. *Cancer Cell*. 2021;39:1091-1098.
8. Marra A, Generali D, Zagami P, et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. *Ann Oncol*. 2021;32(1):113-119.
9. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood*. 2021;137(23):3165-3173.
10. Oekelen OV, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell*. 2021;39:1028-1029.
11. Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. *Blood Advances*. 2021;5(12):2624-2643.
12. Dhakal B, Abedin S, Fenske T, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy. *Blood*. 2021;Online ahead of print.
13. Bradley BT, Bryan A, Fink SL, et al. Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity. *J Clin Microbiol*. 2021;59(9):e0098921.
14. Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines. *Cancer Cell*. 2021;39(8):1031-1033.
15. Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. *Haematologica*. 2021;106(4):978-986.
16. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. *Blood*. 2011;118(26):6769-6771.

17. Wadhera RK, Wadhera P, Gaba P, et al. Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. *JAMA*. 2020;323(21):2192–2195.
18. Khubchandani J, Macias Y. COVID-19 vaccination hesitancy in Hispanics and African-Americans: A review and recommendations for practice. *Brain Behav Immun Health*. 2021;15:100277.

Table 1. Baseline Characteristics and Types of Cancer Therapy

	Total (N=116)	Spike Antibody Positive (N=100)	Spike Antibody Negative (N=16)	P-value
Patient Characteristics				
Age (years), median [range]	70.5 [27-91]	70.5 [27-89]	69 [32-91]	0.11
Sex (male), n (%)	65 (56%)	53 (53%)	12 (75%)	0.11
Race, n (%)				0.36
Black	32 (28%)	30 (30%)	2 (13%)	0.23
Hispanic	45 (39%)	39 (39%)	6 (38%)	1.00
White	30 (26%)	23 (23%)	7 (44%)	0.12
Asian	2 (1%)	2 (2%)	0 (0%)	1.00
Other/Unknown	7 (6%)	6 (6%)	1 (6%)	1.00
Hematologic malignancy, n (%)*				0.003**
Acute Leukemia	8 (7%)	8 (8%)	0 (0%)	0.60
Castleman Disease	1 (1%)	1 (1%)	0 (0%)	1.00
Hodgkin Lymphoma	4 (3%)	3 (3%)	1 (6%)	0.45
MDS	18 (16%)	17 (17%)	1 (6%)	0.46
MPN	3 (3%)	3 (3%)	0 (0%)	1.00
Non-Hodgkin Lymphoma	40 (34%)	27 (27%)	13 (81%)	0.0004**
Plasma Cell Neoplasm	42 (36%)	41 (41%)	1 (6%)	0.06
Hematologic Malignancy category, n (%)				0.0002**
Lymphoid	47 (41%)	33 (33%)	14 (88%)	0.00005**
Myeloid	27 (23%)	26 (26%)	1 (6%)	0.11
Plasma Cell Neoplasm	42 (36%)	41 (41%)	1 (6%)	0.02**
Prior COVID infection, n (%)				
Yes	15 (13%)	13 (13%)	2 (13%)	1.00
No	101 (87%)	87 (87%)	14 (87%)	
Cancer status at time vaccine, n (%)				0.10
Active	49 (42%)	46 (46%)	3 (19%)	0.17
Progressive disease/relapse	19 (17%)	15 (15%)	4 (25%)	0.55
Remission	48 (41%)	39 (39%)	9 (56%)	0.55
Active cancer therapy at vaccination, n (%)				
Yes	69 (59%)	60 (60%)	9 (56%)	0.79
No	47 (41%)	40 (40%)	7 (44%)	
Transplant, n (%)				0.79
Autologous Stem Cell Transplant	43 (37%)	37 (37%)	6 (38%)	0.49
Allogeneic Stem Cell Transplant	4 (3%)	3 (3%)	1 (6%)	0.49
CAR-T therapy, n (%)	7 (6%)	1 (1%)	6 (38%)	0.00002**
Stem cell transplant, n (%)	47 (41%)	40 (40%)	7 (44%)	0.79

Type of Vaccine, n (%)				0.50
Johnson & Johnson	10 (9%)	10 (10%)	0 (0%)	0.35
Moderna	36 (31%)	30 (30%)	6 (38%)	0.57
Pfizer	70 (60%)	60 (60%)	10 (62%)	1.0
Last vaccine dose to Spike IgG testing (days), median [range]	40 [14-154]	45 [14-127]	41 [15-154]	0.71
Spike IgG (AU/mL), median [range]	2157 [<50-50000]	3608 [51-50000]	< 50	0.32
Johnson & Johnson	1078 [138-50000]	1078 [235-50000]	< 50	
Moderna	5290 [50-50000]	6766 [236-50000]	< 50	
Pfizer	1697 [50-50000]	2581 [51-50000]	< 50	
Adverse events post-first dose, n (%)				0.71
None	64 (64%)	55 (55%)	9 (56%)	0.77
Mild/Moderate	35 (35%)	31 (31%)	4 (25%)	1.0
Severe	4 (4%)	4 (4%)	0 (0%)	1.0
Unknown	13 (13%)	10 (10%)	3 (19%)	0.39
Adverse events post-second dose, n (%)	(N=106)	(N=90)	(N=16)	0.92
None	53 (50%)	44 (49%)	9 (56%)	0.77
Mild/Moderate	31 (29%)	27 (30%)	4 (25%)	0.78
Severe	5 (5%)	5 (5%)	0 (0%)	1.0
Unknown	16 (15%)	14 (16%)	3 (19%)	0.72
Types of Cancer Therapy				
Antibody-drug conjugate, n (%)	2 (2%)	1 (1%)	1 (6%)	0.23
Anti-CD19 antibody therapy, n (%)	1 (1%)	0 (0%)	1 (6%)	0.14
Anti-CD20 antibody therapy, n (%)	36 (31%)	22 (22%)	14 (88%)	0.02**
Less than 6 months	12 (10%)	5 (5%)	7 (44%)	
Greater than 6 months	24 (21%)	17 (17%)	7 (44%)	
Anti-CD30 antibody therapy, n (%)	1 (1%)	1 (1%)	0 (0%)	1.00
Anti-CD38 antibody therapy, n (%)	16 (14%)	15 (15%)	1 (6%)	0.69
Anti-IL-6 antibody therapy, n (%)	3 (3%)	1 (1%)	2 (13%)	0.05
Anti-viral therapy, n (%)	4 (3%)	3 (3%)	1 (6%)	0.45
BCL-2 inhibitor, n (%)	11 (9%)	8 (8%)	3 (19%)	0.18
BTK inhibitor, n (%)	4 (3%)	2 (2%)	2 (13%)	0.09
CAR-T therapy, n (%)				
Greater than 1 year	5 (4%)	0 (0%)	5 (31%)	0.29
Spike IgG titer	7 (6%)	1 (1%)	6 (38%)	0.16
Clinical Trial (experimental therapy), n (%)	7 (6%)	7 (7%)	0 (0%)	0.59
Current Steroid Use, n (%)	26 (22%)	21 (21%)	5 (31%)	0.35
Cytotoxic Chemotherapy, n (%)	70 (60%)	55 (55%)	15 (94%)	0.002**
Hormonal therapy (ADT, OFS, and AI), n (%)	5 (4%)	5 (5%)	0 (0%)	1.00
Immune checkpoint inhibitor, n (%)	2 (2%)	1 (1%)	1 (6%)	0.26
Immunomodulatory agent, n (%)	40 (34%)	39 (39%)	1 (6%)	0.01**
IVIG, n (%)	8 (7%)	4 (4%)	4 (25%)	0.01**
No treatment, n (%)	5 (4%)	5 (5%)	0 (0%)	1.00
Proteasome inhibitor, n (%)	39 (34%)	38 (38%)	1 (6%)	0.01**
Radiation, n (%)	22 (19%)	20 (20%)	2 (13%)	0.73

Stem cell transplant, n (%)				
Greater than 1 year	38 (33%)	32 (32%)	6 (38%)	0.78
Spike IgG titer	47 (41%)	40 (40%)	7 (44%)	0.69
Supportive Care, n (%)	11 (9%)	11 (11%)	0 (0%)	0.36
Surgery, n (%)	11 (9%)	10 (10%)	1 (6%)	1.00
TGFβ inhibitor, n (%)	4 (3%)	4 (4%)	0 (0%)	1.00
Tyrosine kinase inhibitor, n (%)	5 (4%)	5 (5%)	0 (0%)	1.00

ADT, Androgen deprivation therapy; BCL-2, B cell lymphoma 2; BTK, Bruton's tyrosine kinase; OFS, Ovarian function suppression; AI, Aromatase inhibitors; IVIG, Intravenous immune globulin; TGFβ, Transforming growth factor beta.

*Acute leukemia (ALL, Acute lymphocytic leukemia; AML, Acute myeloid leukemia); MDS, Myelodysplastic syndrome; MPN, Myeloproliferative neoplasm (CML, Chronic Myeloid Leukemia; MDS/MPN); Non-Hodgkin Lymphoma (ATLL, Adult T-cell Leukemia/Lymphoma; Burkitt's Lymphoma; CLL, Chronic Lymphocytic Lymphoma; DLBCL, Diffuse Large B-cell Lymphoma; Follicular Lymphoma; MALT Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Mycosis Fungoides; Peripheral T-cell Lymphoma; Primary CNS Lymphoma; Waldenstrom's Macroglobulinemia); Plasma Cell Neoplasm (Multiple Myeloma; Amyloidosis; Plasma Cell Leukemia)

** = Statistically significant